Pharma Industry News

FDA approves J&J’s non-chemotherapy combination regimen for rare blood cancer

Approval expands the label for Imbruvica in WM to include combination use with rituximabOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]